UCB SA - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
UCBJY Over the counter 2834 www.ucb.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for UCB SA

Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth - Jul 18th, 2025 7:54 am
UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock? - Jul 14th, 2025 10:00 am
Here's What Could Help UCB (UCBJY) Maintain Its Recent Price Strength - Jul 9th, 2025 6:50 am
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community - Jul 8th, 2025 5:00 am
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder - Jun 27th, 2025 5:00 am
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference - Jun 20th, 2025 5:00 am
Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S. - Jun 17th, 2025 6:22 am
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity - Jun 12th, 2025 10:30 am
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity - Jun 11th, 2025 11:00 pm
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis - Jun 11th, 2025 10:16 am
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences - May 19th, 2025 10:30 am
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025 - Apr 3rd, 2025 5:00 am
UCB Convening Notice to the General Meeting of the Shareholders 2025 - Mar 21st, 2025 12:00 am
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference - Mar 19th, 2025 5:00 am
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome - Mar 12th, 2025 11:54 am
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders - Mar 7th, 2025 11:52 am
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis - Mar 7th, 2025 6:00 am
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden - Mar 7th, 2025 6:00 am
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Mar 3rd, 2025 6:01 pm
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth - Feb 27th, 2025 5:00 am